Roivant Sciences (ROIV) Total Current Liabilities (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Total Current Liabilities came in at $281.2 million in Q1 2026, up 88.24% YoY from $149.4 million in Q1 2025, and down 40.04% on a QoQ basis from $469.1 million in Q4 2025.
Roivant Sciences (ROIV) Total Current Liabilities (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Total Current Liabilities data on file, last reported at $281.2 million in Q1 2026.
- Quarterly Total Current Liabilities rose 88.24% year-over-year to $281.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.2 million (up 88.24% YoY) and the FY2026 annual result came in at $281.2 million, up 88.24% from the prior year.
- Total Current Liabilities fell to $281.2 million in Q1 2026, from $469.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $556.2 million in Q3 2024 to a low of $877000.0 in Q4 2022.
- A 5-year average of $199.0 million and a median of $190.1 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 99.45% — and 2024, when it surged 38448.09%.
- Tracing ROIV's Total Current Liabilities over 5 years: stood at $877000.0 in 2022, then surged by 35370.24% to $311.1 million in 2023, then rose by 5.96% to $329.6 million in 2024, then surged by 42.3% to $469.1 million in 2025, then slumped by 40.04% to $281.2 million in 2026.
- The last three Total Current Liabilities figures came in at $281.2 million (Q1 2026), $469.1 million (Q4 2025), and $133.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 283.60 Mn |
| Mar 31, 2026 | 281.24 Mn |
| Dec 31, 2025 | 469.06 Mn |
| Sep 30, 2025 | 133.86 Mn |
| Jun 30, 2025 | 113.87 Mn |
| Mar 31, 2025 | 149.41 Mn |
| Dec 31, 2024 | 329.61 Mn |
| Sep 30, 2024 | 556.25 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 266.76 Mn |
| Dec 31, 2023 | 311.07 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 8.07 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 877,000.00 |
| Sep 30, 2022 | 230.74 Mn |
| Jun 30, 2022 | 328.92 Mn |
| Dec 31, 2021 | 160.71 Mn |
| Sep 30, 2021 | 303.44 Mn |
| Jun 30, 2021 | 209.16 Mn |